{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:01:44Z","timestamp":1790715704186,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10238-020-00671-y","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:02:43Z","timestamp":1604077363000},"page":"167-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":267,"title":["Emerging treatment strategies for COVID-19 infection"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Korompoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis-Georgios","family":"Tzanninis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"671_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"671_CR2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"671_CR3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vox.12926","volume":"115","author":"P Tiberghien","year":"2020","unstructured":"Tiberghien P, de Lambalerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang. 2020;115(6):488\u201394.","journal-title":"Vox Sang."},{"key":"671_CR4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545\u20138.","journal-title":"J Clin Invest"},{"key":"671_CR5","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"30","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;30:2757\u201365.","journal-title":"J Clin Invest"},{"key":"671_CR6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","volume":"24","author":"A Casadevall","year":"2003","unstructured":"Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24:474\u20138.","journal-title":"Trends Immunol"},{"key":"671_CR7","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","volume":"323","author":"JD Roback","year":"2020","unstructured":"Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323:1561\u20132.","journal-title":"JAMA"},{"issue":"7809","key":"671_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Woelfel","year":"2020","unstructured":"Woelfel R, Corman M, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465\u20139.","journal-title":"Nature."},{"key":"671_CR9","first-page":"26","volume":"2020","author":"NMA Okba","year":"2019","unstructured":"Okba NMA, Muller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 2019;2020:26.","journal-title":"Emerg Infect Dis"},{"key":"671_CR10","doi-asserted-by":"crossref","unstructured":"Zhao J, Yuan Q, Wang H et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344","DOI":"10.1093\/cid\/ciaa344"},{"key":"671_CR11","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582\u20139.","journal-title":"JAMA"},{"issue":"1","key":"671_CR12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","volume":"158","author":"B Zhang","year":"2020","unstructured":"Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020;158(1):e9\u201313.","journal-title":"Chest."},{"key":"671_CR13","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"671_CR14","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1097\/HS9.0000000000000409","volume":"4","author":"T Psaltopoulou","year":"2020","unstructured":"Psaltopoulou T, Sergentanis TN, Pappa V, et al. The emerging role of convalescent plasma in the treatment of COVID-19. HemaSphere. 2020;4:e409.","journal-title":"HemaSphere"},{"issue":"8","key":"671_CR15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","volume":"190","author":"E Salazar","year":"2020","unstructured":"Salazar E, Perez KK, Ashraf M, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020;190(8):1680\u201390.","journal-title":"Am J Pathol."},{"issue":"9","key":"671_CR16","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","volume":"130","author":"MJ Joyner","year":"2020","unstructured":"Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791\u20137.","journal-title":"J Clin Invest."},{"issue":"20","key":"671_CR17","first-page":"30470","volume":"S1473\u20133099","author":"RS Tedder","year":"2020","unstructured":"Tedder RS, Semple MG. Appropriate selection of convalescent plasma donors for COVID-19. Lancet Infect Dis. 2020;S1473\u20133099(20):30470\u20139.","journal-title":"Lancet Infect Dis."},{"issue":"7","key":"671_CR18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ajh.25829","volume":"95","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Kastritis E, et al. Haematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834\u201347.","journal-title":"Am J Hematol"},{"key":"671_CR19","doi-asserted-by":"publisher","unstructured":"Liu S, Lin H-M, Baine I et al. Convalescent plasma treatment of severe COVID-19: a matched control study. https:\/\/doi.org\/10.1101\/2020.05.20.20102236.","DOI":"10.1101\/2020.05.20.20102236"},{"key":"671_CR20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","volume":"38","author":"A Casadevall","year":"1994","unstructured":"Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38:1695\u2013702.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"671_CR21","first-page":"e02015","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015\u201319.","journal-title":"J Virol."},{"issue":"396","key":"671_CR22","doi-asserted-by":"crossref","first-page":"eaa13653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.","journal-title":"Sci Transl Med."},{"issue":"5","key":"671_CR23","doi-asserted-by":"crossref","first-page":"e00399","DOI":"10.1128\/AAC.00399-20","volume":"64","author":"MA Martinez","year":"2020","unstructured":"Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399\u201320.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"671_CR24","first-page":"994","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19: preliminary report. N Engl J Med. 2020;383(10):994.","journal-title":"N Engl J Med."},{"key":"671_CR25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569\u201378.","journal-title":"Lancet"},{"key":"671_CR26","doi-asserted-by":"crossref","unstructured":"Goldman JD, Lye DCB, Hui DS et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;NEJMoa2015301","DOI":"10.1056\/NEJMoa2015301"},{"key":"671_CR27","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327\u201336.","journal-title":"N Engl J Med"},{"key":"671_CR28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155\u201366.","journal-title":"Nat Rev Rheumatol"},{"key":"671_CR29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3949\/ccjm.85a.17034","volume":"85","author":"EA Shippey","year":"2018","unstructured":"Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med. 2018;85:459\u201367.","journal-title":"Cleve Clin J Med"},{"issue":"15","key":"671_CR30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732\u20139.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"671_CR31","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.","journal-title":"Int J Antimicrob Agents."},{"key":"671_CR32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M20-1223","volume":"172","author":"AHJ Kim","year":"2020","unstructured":"Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819\u201321.","journal-title":"Ann Intern Med"},{"key":"671_CR33","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.","journal-title":"Travel Med Infect Dis"},{"key":"671_CR34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","volume":"50","author":"JM Molina","year":"2020","unstructured":"Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.","journal-title":"Med Mal Infect"},{"key":"671_CR35","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","volume":"369","author":"W Tang","year":"2020","unstructured":"Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.","journal-title":"BMJ"},{"key":"671_CR36","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382:2411\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"671_CR37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517\u201325.","journal-title":"N Engl J Med."},{"key":"671_CR38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252\u20136.","journal-title":"Thorax"},{"key":"671_CR39","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695\u2013704.","journal-title":"Lancet"},{"key":"671_CR40","doi-asserted-by":"crossref","unstructured":"Li Y, Xie Z, Lin W et al. Efficacy and Safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Med 2020 (in press).","DOI":"10.1016\/j.medj.2020.04.001"},{"key":"671_CR41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","volume":"12","author":"M Huang","year":"2020","unstructured":"Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12:322\u20135.","journal-title":"J Mol Cell Biol"},{"key":"671_CR42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat F, Krammer F. SARS-CoV-2 Vaccines: status report. Immunity. 2020;52:583\u20139.","journal-title":"Immunity"},{"key":"671_CR43","doi-asserted-by":"publisher","unstructured":"Chen C, Zhang Y, Huang J et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. https:\/\/doi.org\/10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"671_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","volume":"97","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis. 2020;97:7\u201310.","journal-title":"Int J Infect Dis"},{"key":"671_CR45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jth.14830","volume":"18","author":"S Cui","year":"2020","unstructured":"Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421\u20134.","journal-title":"J Thromb Haemost"},{"key":"671_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145\u20137.","journal-title":"Thromb Res"},{"key":"671_CR47","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094\u20139.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"671_CR48","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811\u20138.","journal-title":"JAMA Cardiol."},{"key":"671_CR49","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"E Driggin","year":"2020","unstructured":"Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"671_CR50","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","volume":"18","author":"J Thachil","year":"2020","unstructured":"Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023\u20136.","journal-title":"J Thromb Haemost"},{"key":"671_CR51","unstructured":"(ASH) ASoH. COVID-19 and VTE\/anticoagulation: frequently asked questions Version 2.1. 2020."},{"key":"671_CR52","unstructured":"(ASH) ASoH. COVID-19 and coagulopathy: frequently asked questions Version 2.0. 2020."},{"key":"671_CR53","unstructured":"Panel. C-TG. Coronavirus Diseases 2019 (COVID-19) Treatment Guidelines. National Institutes of Health."},{"key":"671_CR54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727\u201332.","journal-title":"Emerg Microbes Infect"},{"key":"671_CR55","unstructured":"(ASH) ASoH. COVID-19 and pulmonary embolism: frequently asked questions Version 1.0. 2020."},{"issue":"7","key":"671_CR56","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/jth.14828","volume":"18","author":"J Wang","year":"2020","unstructured":"Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752\u20135.","journal-title":"J Thromb Haemost."},{"key":"671_CR57","unstructured":"Raffaele. IS. Defibrotide in COVID-19 pneumonia (DEFI-VID19)."},{"key":"671_CR58","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117:10970\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"671_CR59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","volume":"18","author":"B Fu","year":"2020","unstructured":"Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18:164.","journal-title":"J Transl Med"},{"key":"671_CR60","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55:105954.","journal-title":"Int J Antimicrob Agents"},{"key":"671_CR61","doi-asserted-by":"crossref","unstructured":"Gritti G, Raimondi A, Ripamonti D, al. e. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. EClinicalMedicine 2020; published online, 100418.","DOI":"10.1101\/2020.04.01.20048561"},{"key":"671_CR62","doi-asserted-by":"crossref","unstructured":"Somers EC, Eschenauer GA, Troost JP et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020;ciaa954.","DOI":"10.1101\/2020.05.29.20117358"},{"key":"671_CR63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","volume":"11","author":"V Giudice","year":"2020","unstructured":"Giudice V, Pagliano P, Vatrella A, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857.","journal-title":"Front Pharmacol"},{"key":"671_CR64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","volume":"324","author":"M Marovich","year":"2020","unstructured":"Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324:131\u20132.","journal-title":"JAMA"},{"issue":"4","key":"671_CR65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40264-019-00900-8","volume":"43","author":"N Moore","year":"2020","unstructured":"Moore N. Coronary risks associated with diclofenac and other NSAIDs: an update. Drug Saf. 2020;43(4):301\u201318.","journal-title":"Drug Saf."},{"key":"671_CR66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/infdis\/jiw603","volume":"215","author":"YC Wen","year":"2017","unstructured":"Wen YC, Hsiao FY, Chan KA, et al. Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study. J Infect Dis. 2017;215:503\u20139.","journal-title":"J Infect Dis"},{"key":"671_CR67","first-page":"e21","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respir Med. 2020;8:e21.","journal-title":"Respir Med"},{"key":"671_CR68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221\u20134.","journal-title":"Nature"},{"key":"671_CR69","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/jcm8060786","volume":"8","author":"G Voiriot","year":"2019","unstructured":"Voiriot G, Philippot Q, Elabbadi A, et al. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019;8:786.","journal-title":"J Clin Med"},{"key":"671_CR70","doi-asserted-by":"crossref","first-page":"m1185","DOI":"10.1136\/bmj.m1185","volume":"368","author":"P Little","year":"2020","unstructured":"Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.","journal-title":"BMJ"},{"key":"671_CR71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.chest.2020.03.040","volume":"158","author":"M Sodhi","year":"2020","unstructured":"Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: Causal or confounded? Chest. 2020;158:55\u20136.","journal-title":"Chest"},{"issue":"5","key":"671_CR72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/dtb.2020.000021","volume":"58","author":"Team D","year":"2020","unstructured":"Team D. EMA advice on the use of NSAIDs for Covid-19. Drug Ther Bull. 2020;58(5):69.","journal-title":"Drug Ther Bull."},{"key":"671_CR73","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"L Shang","year":"2020","unstructured":"Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683\u20134.","journal-title":"Lancet"},{"key":"671_CR74","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transpl. 2020;39:405\u20137.","journal-title":"J Heart Lung Transpl"},{"key":"671_CR75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757\u201367.","journal-title":"Am J Respir Crit Care Med"},{"key":"671_CR76","first-page":"e98\u2013106","volume":"48","author":"LE Lansbury","year":"2019","unstructured":"Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2019;48:e98\u2013106.","journal-title":"Crit Care Med"},{"key":"671_CR77","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","volume":"31","author":"N Lee","year":"2004","unstructured":"Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304\u20139.","journal-title":"J Clin Virol"},{"key":"671_CR78","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.","journal-title":"PLoS Med"},{"key":"671_CR79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","volume":"8","author":"J Villar","year":"2020","unstructured":"Villar J, Ferrando C, Mart\u00ednez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267\u201376.","journal-title":"Lancet Respir Med"},{"key":"671_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2019.4346","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:1\u201311.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"671_CR81","doi-asserted-by":"crossref","first-page":"e01168","DOI":"10.1128\/AAC.01168-20","volume":"64","author":"A Fern\u00e1ndez Cruz","year":"2020","unstructured":"Fern\u00e1ndez Cruz A, Ruiz-Antor\u00e1n B, Mu\u00f1oz G\u00f3mez A, et al. Impact of glucocorticoid treatment in SARS-COV-2 infection mortality: a retrospective controlled cohort study. Antimicrob Agents Chemother. 2020;64(9):e01168\u201320.","journal-title":"Antimicrob Agents Chemother."},{"key":"671_CR82","unstructured":"Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with Covid-19: preliminary report. N Engl J Med. 2020;NEJMoa2021436"},{"key":"671_CR83","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"671_CR84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475\u201381.","journal-title":"Lancet Respir Med"},{"key":"671_CR85","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"671_CR86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/pharmaceutics11020075","volume":"11","author":"JA McGrath","year":"2019","unstructured":"McGrath JA, O\u2019Sullivan A, Bennett G, et al. Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics. 2019;11:75.","journal-title":"Pharmaceutics"},{"key":"671_CR87","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.waojou.2020.100125","volume":"13","author":"M Levin","year":"2020","unstructured":"Levin M, Morais-Almeida M, Ansotegui IJ, et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020;13:100125.","journal-title":"World Allergy Organ J"},{"key":"671_CR88","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","volume":"48","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, M\u00f8ller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48:e440\u201369.","journal-title":"Crit Care Med"},{"key":"671_CR89","doi-asserted-by":"crossref","unstructured":"Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;2016(6):CD002787","DOI":"10.1002\/14651858.CD002787.pub3"},{"key":"671_CR90","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"671_CR91","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa1503326","volume":"372","author":"JP Frat","year":"2015","unstructured":"Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185\u201396.","journal-title":"N Engl J Med"},{"key":"671_CR92","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajem.2017.07.083","volume":"36","author":"YN Ni","year":"2018","unstructured":"Ni YN, Luo J, Yu H, et al. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation: a systematic review and meta-analysis. Am J Emerg Med. 2018;36:226\u201333.","journal-title":"Am J Emerg Med"},{"key":"671_CR93","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763\u201370.","journal-title":"Lancet"},{"key":"671_CR94","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","volume":"180","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345\u201355.","journal-title":"JAMA Intern Med"},{"key":"671_CR95","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S2213-2600(20)30279-4","volume":"8","author":"L Camporota","year":"2020","unstructured":"Camporota L, Vasques F, Sanderson B, et al. Identification of pathophysiological patterns for triage and respiratory support in COVID-19. Lancet Respir Med. 2020;8:752\u20134.","journal-title":"Lancet Respir Med"},{"key":"671_CR96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120\u20138.","journal-title":"N Engl J Med"},{"key":"671_CR97","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","volume":"6","author":"D Gouglas","year":"2018","unstructured":"Gouglas D, Le Thanh T, Henderson K, et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health. 2018;6:e1386\u201396.","journal-title":"Lancet Glob Health"},{"key":"671_CR98","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","volume":"17","author":"P Yang","year":"2020","unstructured":"Yang P, Wang X. COVID-19: a new challenge for human beings. Cell Mol Immunol. 2020;17:555\u20137.","journal-title":"Cell Mol Immunol"},{"key":"671_CR99","doi-asserted-by":"crossref","unstructured":"Wrapp D, Wang N, Corbett KS et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. bioRxiv 2020.","DOI":"10.1101\/2020.02.11.944462"},{"key":"671_CR100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/d41586-020-01221-y","volume":"580","author":"E Callaway","year":"2020","unstructured":"Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576\u20137.","journal-title":"Nature"},{"key":"671_CR101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-020-0170-0","volume":"5","author":"W Shang","year":"2020","unstructured":"Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020;5:18.","journal-title":"NPJ Vaccines"},{"key":"671_CR102","unstructured":"Jackson LA, Anderson EJ, Rouphael NG et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med. 2020;NEJMoa2022483."},{"key":"671_CR103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/d41587-020-00005-z","volume":"38","author":"J Hodgson","year":"2020","unstructured":"Hodgson J. The pandemic pipeline. Nat Biotechnol. 2020;38:523\u201332.","journal-title":"Nat Biotechnol"},{"key":"671_CR104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"T Le Thanh","year":"2020","unstructured":"Le Thanh T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"671_CR105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","volume":"20","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020;20:816\u201326.","journal-title":"Lancet Infect Dis"},{"key":"671_CR106","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969\u201373.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-020-00671-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:29:32Z","timestamp":1618788572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-020-00671-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["671"],"URL":"https:\/\/doi.org\/10.1007\/s10238-020-00671-y","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}